NASDAQ:SGTX - Nasdaq - US82657L2060 - Common Stock - Currency: USD
Taking everything into account, SGTX scores 1 out of 10 in our fundamental rating. SGTX was compared to 559 industry peers in the Biotechnology industry. SGTX may be in some trouble as it scores bad on both profitability and health. SGTX has a expensive valuation and it also scores bad on growth.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | N/A | ||
ROE | N/A | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.31 | ||
Debt/FCF | N/A | ||
Altman-Z | -4.91 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 2.23 | ||
Quick Ratio | 2.23 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
22.47
-0.59 (-2.56%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 3.86 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 1.7 | ||
P/tB | 1.7 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | N/A | ||
ROE | N/A | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.31 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 38.88% | ||
Cap/Sales | N/A | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 2.23 | ||
Quick Ratio | 2.23 | ||
Altman-Z | -4.91 |